Jiexia Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jiexia Zhang has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Bo Zhu
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
12 shared publications - Chaopin Yang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
12 shared publications - Guojun Liu
Shandong Qilu Stem Cell Engineering Co. Ltd., Shandong, P.R. China
12 shared publications - Haiwen Chen
State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China
12 shared publications - Pingjuan Liu
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
12 shared publications - Qinqin Ren
State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China
12 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (6) , 172
A recurrence risk prediction model and recurrence patterns in pulmonary lymphoepithelial carcinoma based on clinical and dynamic hematologic parameters
Background: Pulmonary lymphoepithelial carcinoma (pLELC) is a rare Epstein-Barr virus (EBV)-associated non-small cell lung cancer (NSCLC). In patients with resected pLELC, postoperative recurrence is the major barrier to long-term survival. However, predictors of recurrence remain unclear, and reliable risk prediction models are lacking. This study aimed to develop a recurrence risk prediction model for patients with resected pLELC based on clinical and dynamic hematologic parameters and to characterize postoperative recurrence patterns. Methods: We retrospectively analyzed patients who underwent radical resection for pLELC. Recurrence-related variables were screened by univariable and stepwise multivariable Cox regression to construct a predictive model. The model’s performance was assessed via receiver operating characteristic (ROC) analysis, the concordance index (C-index), and bootstrap internal validation, with a comparison against the tumor-node-metastasis (TNM) staging system. Recurrence sites and their prognostic implications were also evaluated. Results: Of 238 patients, 57 developed recurrences. Independent predictors of recurrence were node (N) stage, central tumor location, elevated preoperative D-dimer, postoperative platelet count increase, and elevated postoperative neutrophil-to-lymphocyte ratio (NLR). The model demonstrated strong discriminative performance in the training cohort, with 1-, 3-, and 5-year of area under the curves (AUCs) of 0.822, 0.792, and 0.744, respectively, outperforming the conventional TNM staging system. Internal validation yielded a C-index of 0.752. Among patients with recurrence, the median disease-free survival (DFS) was 21.8 months. Most recurrences were locoregional (76.0%), and those with distant metastasis experienced significantly poorer post-recurrence survival (PRS) (P=0.04). Conclusions: Our recurrence prediction model for resected pLELC, which integrates clinical and dynamic hematologic factors, outperformed TNM staging. It provides a basis for stratifying postoperative surveillance and guiding early intervention in high-risk patients. Additionally, patients with distant metastasis had worse PRS than those with locoregional relapse, indicating distinct prognostic implications based on recurrence pattern.
- 1 June 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (6) , 172
Open AccessA recurrence risk prediction model and recurrence patterns in pulmonary lymphoepithelial carcinoma based on clinical and dynamic hematologic parameters
Background: Pulmonary lymphoepithelial carcinoma (pLELC) is a rare Epstein-Barr virus (EBV)-associated non-small cell lung cancer (NSCLC). In patients with resected pLELC, postoperative recurrence is the major barrier to long-term survival. However, predictors of recurrence remain unclear, and reliable risk prediction models are lacking. This study aimed to develop a recurrence risk prediction model for patients with resected pLELC based on clinical and dynamic hematologic parameters and to characterize postoperative recurrence patterns. Methods: We retrospectively analyzed patients who underwent radical resection for pLELC. Recurrence-related variables were screened by univariable and stepwise multivariable Cox regression to construct a predictive model. The model’s performance was assessed via receiver operating characteristic (ROC) analysis, the concordance index (C-index), and bootstrap internal validation, with a comparison against the tumor-node-metastasis (TNM) staging system. Recurrence sites and their prognostic implications were also evaluated. Results: Of 238 patients, 57 developed recurrences. Independent predictors of recurrence were node (N) stage, central tumor location, elevated preoperative D-dimer, postoperative platelet count increase, and elevated postoperative neutrophil-to-lymphocyte ratio (NLR). The model demonstrated strong discriminative performance in the training cohort, with 1-, 3-, and 5-year of area under the curves (AUCs) of 0.822, 0.792, and 0.744, respectively, outperforming the conventional TNM staging system. Internal validation yielded a C-index of 0.752. Among patients with recurrence, the median disease-free survival (DFS) was 21.8 months. Most recurrences were locoregional (76.0%), and those with distant metastasis experienced significantly poorer post-recurrence survival (PRS) (P=0.04). Conclusions: Our recurrence prediction model for resected pLELC, which integrates clinical and dynamic hematologic factors, outperformed TNM staging. It provides a basis for stratifying postoperative surveillance and guiding early intervention in high-risk patients. Additionally, patients with distant metastasis had worse PRS than those with locoregional relapse, indicating distinct prognostic implications based on recurrence pattern.
- Open Access
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1680523
Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an aggressive malignancy with poor prognosis, rarely harboring EGFR, ALK, or ROS1 alterations. We report an advanced SMARCA4-dNSCLC case with brain metastasis exhibiting a novel CTNND2-ALK/EML4-ALK double-fusion. Following platinum-based chemotherapy and brain radiotherapy, next-generation sequencing identified the dual fusions (abundances: 2.6% and 5.2%), confirmed by ALK protein expression. The patient subsequently received ceritinib (750 mg/day). After 3 months, targeted lesions regressed significantly, and progression-free survival exceeded 24 months with ongoing response. This demonstrates efficacy of the ALK inhibitor ceritinib in ALK-rearranged SMARCA4-dNSCLC and underscores the clinical value of genomic-guided therapy.
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1680523
Open AccessCeritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an aggressive malignancy with poor prognosis, rarely harboring EGFR, ALK, or ROS1 alterations. We report an advanced SMARCA4-dNSCLC case with brain metastasis exhibiting a novel CTNND2-ALK/EML4-ALK double-fusion. Following platinum-based chemotherapy and brain radiotherapy, next-generation sequencing identified the dual fusions (abundances: 2.6% and 5.2%), confirmed by ALK protein expression. The patient subsequently received ceritinib (750 mg/day). After 3 months, targeted lesions regressed significantly, and progression-free survival exceeded 24 months with ongoing response. This demonstrates efficacy of the ALK inhibitor ceritinib in ALK-rearranged SMARCA4-dNSCLC and underscores the clinical value of genomic-guided therapy.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables
- Open Access
- 31 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1605900
Induction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review
Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of non-small cell lung cancer (NSCLC) that is closely associated with Epstein-Barr virus (EBV) infection. While radiotherapy after induction chemotherapy have shown marked efficacy in nasopharyngeal carcinoma (NPC), its effectiveness in pLELC remains uncertain. A female with stage IIIB pLELC was treated with 4 cycles of gemcitabine plus cisplatin, achieving partial response(PR), followed by radical radiotherapy. Patients achieved clinical complete response(CR) with recurrence-free for over five years. This case highlights the potential of induction chemotherapy as an effective treatment for locally advanced pLELC.
- 31 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1605900
Open AccessInduction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review
Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of non-small cell lung cancer (NSCLC) that is closely associated with Epstein-Barr virus (EBV) infection. While radiotherapy after induction chemotherapy have shown marked efficacy in nasopharyngeal carcinoma (NPC), its effectiveness in pLELC remains uncertain. A female with stage IIIB pLELC was treated with 4 cycles of gemcitabine plus cisplatin, achieving partial response(PR), followed by radical radiotherapy. Patients achieved clinical complete response(CR) with recurrence-free for over five years. This case highlights the potential of induction chemotherapy as an effective treatment for locally advanced pLELC.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV+ NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV-positive NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. Based on our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV+ NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV-positive NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. Based on our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)–associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV-positive (EBV+) NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV+ NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. On the basis of our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)–associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV-positive (EBV+) NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV+ NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. On the basis of our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)–associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV-positive (EBV+) NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV+ NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. On the basis of our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)–associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV-positive (EBV+) NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV+ NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. On the basis of our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables